Kindred Biosciences, Inc. released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study. This study was a randomized, single-blind, placebo-controlled study that enrolled 32 cats (16 in the KIND-010 group, 16 in the placebo group).

The objective was to demonstrate the effectiveness and safety of KIND-010 for the stimulation of weight gain in cats under clinical conditions.  At Week 2, mean weight of cats in the KIND-010 group was 4.32 kg (percent increase from Day 1 was 3.25%) versus 3.98 kg (percent increase from Day 1 was -1.65%) in the placebo group (p=0.0042). The company also announced that the pivotal effectiveness study (KB105) for KIND-010 for the management of weight loss in cats is over halfway enrolled, ahead of schedule.  This randomized, double-blind, placebo-controlled study was concurred upon by FDA and will enroll a minimum of 200 cats (100 KIND-010/100 placebo) to assess the mean percent change in body weight from Day 1 to Week 2.  The Company conducted a pre-specified, interim sample-size reassessment once over 100 cats were enrolled and determined that the original sample size does not need to be increased.